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Abstract
Background: Radiation-induced diarrhea is frequently observed during pelvic radiotherapy. This study was performed 
to determine the ability of a probiotic containing live lactobacillus acidophilus plus bifidobacterium bifidum to reduce 
the incidence of radiation-induced diarrhea in locally advanced cervical cancer patients.
Methods: Patients who were undergoing pelvic radiotherapy concurrent with weekly cisplatin were randomly 
assigned to a study drug or placebo, in a double-blind study. Diarrhea was graded weekly according the Common 
Toxicity Criteria (CTC) system. Stool consistency and white and red blood cell count in stool were also assessed. The 
primary endpoint was to reduce the incidence of diarrhea, defined by a CTC grade 2 or more, and the need for anti-
diarrheal medication.
Results: A total of 63 patients were enrolled. Grade 2 -3 diarrhea was observed in 45% of the placebo group (n = 31) 
and 9% of the study drug group (n = 32) (p = 0.002). Anti-diarrheal medication use was significantly reduced in the 
placebo group (p = 0.03). The patients in the study drug group had a significantly improved stool consistency (p < 
0.001).
Conclusions: Live lactobacillus acidophilus plus bifidobacterium bifidum reduced the incidence of radiation-induced 
diarrhea and the need for anti-diarrheal medication and had a significant benefits on stool consistency.
Background
Radical radiation therapy to pelvic malignancy carries a
risk of complications to normal tissues around the tumor.
Acute complications affecting the gastrointestinal tract
occur in approximately 80% of patients, but they are usu-
ally mild and only rarely affect the treatment planning [1].
One of the most common acute complications of pelvic
radiotherapy is acute inflammatory change in the small
intestine leading to gastrointestinal symptoms during
treatment because healthy bowel tissue is encompassed
in the radiation field. Acute symptoms include diarrhea,
abdominal pain, tenesmus and nausea, usually starting
during the second or third week of radiotherapy [1,2].
Because of this the incidence of malnutrition in patients
who receive pelvic radiotherapy is 11-33% and up to 83%
of patients lose weight during treatment [3]. The develop-
ment of late gastrointestinal symptoms following pelvic
radiotherapy is not entirely dose related, but depends on
a complex interaction between physical, patient-related,
treatment-related, and genetic factors that is not well
understood [4]; Andreyev et al. have found that in
approximately one-quarter of patients referred with gas-
trointestinal symptoms after radiotherapy the symptoms
are unrelated to the radiotherapy itself [5]. However 5-
10% of patients who have acute gastrointestinal tract
complications during radiotherapy go on to suffer late
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serious gastrointestinal complications [6-8]. These
include bowel obstruction, fistulation and intractable
bleeding. The severity of acute bowel toxicity may prede-
termine the degree of chronic bowel changes [9]. There-
fore early intervention to prevent or reduce acute toxicity
may also have long term benefits.
The intestinal mucosa depends upon the bacterial flora
of the gut and the luminal contents for part of its own
supply of nutrients. Radiation creates changes in bacterial
flora, the vascular permeability of the mucosal cells and
in intestinal motility [9,10]. The ingestion of lactic acid
bacteria has been extensively investigated as a beneficial
dietary adjunct for gastrointestinal disorders in humans
and animals. Lactobacillus has been suggested for the
prevention and treatment of diarrhea induced by E. Coli,
salmonella or shigella [11]. In vitro studies have indicated
that part of this effect may be due to lactobacillus strains
[12-15]. Since dysbiosis of the intestinal flora may be a
promoting factor in radiotherapy-related intestinal prob-
lems, lactobacilli could be used to achieve a more balance
micro-flora during the treatment. Mc Gough et al. [3]
reviewed the original studies in the management of gas-
trointestinal tract side effects in patients undergoing pel-
vic radiotherapy and found that low-fat diets, probiotic
supplementation and an elemental diet may be beneficial
in preventing symptoms. The objective of our study was
to test the efficacy of lactobacillus acidophilus plus bifi-
dobacterium bifidum in reducing the incidence and
severity of diarrhea during pelvic radiotherapy.
Patients and methods
Study design
This was a prospective, randomized, double-blind, pla-
cebo-controlled study. Patients diagnosed with locally
advanced cervical cancer and planned to receive concur-
rent chemoradiotherapy with weekly cisplatin, were ran-
domly assigned to receive either lactobacillus acidophilus
plus bifidobacterium bifidum (Infloran®) or placebo cap-
sules containing magnesium stearate, talc, and purified
water. The placebo was the same size and color as the
study drug. Pre-packaged (blinded) study medication dif-
fering solely in the patient numbers on the medication
package was provided by the sponser. The study drug,
Infloran, is manufactured by Laboratio Farmaceutico SIT,
Mede, Italy. One capsule (250 mg) contains an oral prepa-
ration of a minimum of 1000 million of lactobacillus aci-
dophilus viv. Lyophilisat and minimum of 1000 million of
bifidobacterium bifidum viv. Lyophilisat
Patients were stratified by age, stage, and whole pelvis
radiotherapy technique. Patients were randomly assigned
in a double blind fashion to receive study drug or placebo
in a 1: 1 ratio. The study protocol was submitted to the
ethical review board of Faculty of Medicine, Chiang Mai
University and written informed consent was obtained
from each patient.
Patients
Patients aged at least 18 and not more than 65 years old,
with FIGO stage IIB-IIIB squamous cell carcinoma of
cervix, who were planned to receive the standard treat-
ment for locally advanced cervical cancer of external
beam whole pelvis radiotherapy and brachytherapy plus
weekly cisplatin 40 mg/m2, with ECOG performance sta-
tus 0-1 and negative anti-HIV were included. Exclusion
criteria were; past history of pelvic radiotherapy or
abdominal surgery and diarrhea before the beginning of
this study. Patients who had any gastrointestinal disease,
pregnant and lactating were also excluded from the study.
Treatment
After stratification patients were randomly assigned to
receive 2 × 109 units of a lactobacillus acidophilus plus
bifidobacterium bifidum (equivalent to 2 capsules) two
times a day before meals (morning and evening), begin-
ning 7 days before starting radiotherapy and continuing
everyday during radiotherapy. In the other control group,
an the identical-appearing placebo was administered in
the same schedule. Neither the patient nor the treating
physician knew if the patient was on the study drug or
placebo. Patients were given standard dietry recommen-
dations for radiation thereapy and in addition all yogurt
and other dairy foods produced by fermentation were
forbidden. All subjects were scheduled for external pelvic
radiotherapy with a dose 200 cGy per fraction, five frac-
tions per week. The superior border of fields were at the
L4-L5 junction. The inferior border of fields were at the
bottom of obturator foramen or 2 centimeters lower than
the lowest margin of tumor. The lateral borders were 2
centimeters beyond each pelvic brim. After 4000 cGy, a
midline block was inserted and radiation continued to
5000 cGy. Thereafter the field was reduced to treat only
both parametria to a total dose of 5600 cGy. Every patient
also received four insertions of brachytherapy with Irid-
ium-192 for 700 cGy per fraction. All patients received
weekly cisplatin 40 mg/m2 for 6 weeks during radiother-
apy.
Monitoring and laboratory investigations
Patients were evaluated weekly for the severity of diar-
rhea according to the National Cancer Institute Common
Toxicity Criteria; NCI CTC version 2.0 (grade 0 = none;
grade 1 = increase of < 4 stools/day over pre-treatment;
grade 2 = increase of 4-6 stools/day, or nocturnal stools;
grade 3 = increase of ≥ 7 stools/day or incontinence or
need for parenteral support for dehydration; grade 4 =
physiologic consequences requiring intensive care, or
hemodynamic collapse). The characteristics of the stool,Chitapanarux et al. Radiation Oncology 2010, 5:31
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the presence of white or red blood cells in the stool, the
use of anti-diarrheal medication and the patient's weight
were also recorded weekly. Stool consistency was objec-
tively defined by the technician in the laboratory and cell
counts were analyzed by fresh stool examination (wet
mount). Hematological toxicities were assessed weekly
using the NCI CTC v.2.0. Since the bacilli contained in
the study drug are harmless saprophytes, no adverse
effects can result from their administration, however, an
adverse event or adverse drug reaction was recorded in
each week of treatment. No major adverse events owing
to probiotic supplemaentation were reported in any
study.
Patients were required to return their bottles of study
medication (study drug or placebo) weekly and the num-
ber of capsules returned was documented. Patients who
took < 80% of the medication were considered non-com-
pliant, but were included in the intent-to-treat analysis.
Concomitant medications were recorded. Patients who
requested anti-diarrheal medication were provided with
this by the researcher immediately and recorded with the
patient's concomitant medication record. Only Loper-
amide (2 mg) was used. Adverse events were recorded
weekly.
Statistical Analysis
Continuous variables were described as median and were
compared using the Mann-Whitney test. Categorical
variables were described as percentage and were com-
pared using the Chi-square or Fisher's tests. The p-values
reported are two-tailed and an alpha level of 0.05 was
used to assess statistical significance. Sample size calcula-
tion was calculated by the formula: n = 2 (Zα/2 + Zβ)2 σ2/
(X1-X2): n = 29 each group.
Statistical analyses were performed using SPSS statisti-
cal software (version 11.5, SPSS Inc., 444 N. Michigan,
Chicago, Illinois, USA).
Results
Between January 2007 and April 2009, sixty-three
patients were randomly allocated to receive lactobacillus
acidophilus plus bifidobacterium bifidum (Infloran®) in
32 patients or a placebo in 31 patients (Fig 1). All 63
patients were eligible and assessable. All patients had
undergone concurrent chemoradiotherapy. Age, stage of
disease, performance status, and whole pelvis radiother-
apy technique did not show any difference between the
two groups. Baseline characteristics are shown in Table 1.
During irradiation, diarrhea occurred in all patients. In
the 31 eligible patients who received pelvic radiotherapy
and placebo, rates of Grades 1, 2, and 3 diarrhea during
treatment were 55, 42, and 3%, respectively. For the 32 eli-
gible patients who received radiotherapy and lactobacil-
lus acidophilus plus bifidobacterium bifidum, the overall
rates of grades 1, 2, and 3 diarrhea were 91, 9, and 0%,
respectively. The difference in the severity of diarrhea
was significant p = 0.002 (Table 2). The patients who
received lactobacillus acidophilus plus bifidobacterium
bifidum also had a significantly improved stool consis-
tency (p < 0.001) (Table 2). The prevalence of formed,
soft, and liquid stool was 0%, 35% and 65%, respectively in
placebo group. In contrast, in the study drug group the
prevalence of formed, soft, and liquid stool was 3%, 78%
and 19%, respectively. However white and red blood cell
counts in patients' stool did not differ between the two
groups. The severity of radiation-induced diarrhea is
illustrated by 32% of patients in the placebo group need-
ing anti-diarrheal medication, as against 9% of patients in
the study drug group (p = 0.03). The median overall treat-
ment time and median weight change from the beginning
to the last treatment did not differ between groups (Table
2). There were no adverse events attributable to the study
drug.
Discussion
The present study shows that during pelvic radiotherapy
f o r  c e r v i c a l  c a n c e r  d i a r r h e a  o c c u r r e d  i n  1 0 0 %  o f  o u r
patients. However this side effect was rarely severe, the
median maximum severity of diarrhea was only grade 1.
In Baughan's study [16], median maximum severity of
d i a r r h e a  w a s  a l s o  g r a d e  1 .  A l t h o u g h  d i a r r h e a  u s u a l l y
accompanies rectal mucosal lesions, some authors believe
that it is caused by radiation injury to the small intestine.
Bile acid malabsorption and bacterial contamination by
an aerobic and anaerobic bacteria are common causes of
diarrhea after the radiation treatment of gynecological
cancer. Maintaining intestinal integrity during radiother-
apy significantly influences the quality of life of patients.
Usually severe radiation-induced diarrhea is treated by
medication but it may lead to an interruption in treat-
Figure 1 Trial profile.
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ment. Probiotic nutritional intervention before and dur-
ing radiotherapy may induce a radio-protective effect for
healthy tissues, the mechanism of which is not clear. It is
assumed that probiotics may improve the immune status
of the gut [17]. Also the growth of probiotics may inter-
fere with the growth of pathogenic bacteria because they
compete with pathogenic bacteria for binding sites on
epithelial cells [18]. Previous studies of Lactobillus bacte-
ria for radiation induced diarrhea have produced mixed
results. Two randomly controlled trials were negative,
failing to identify significant improvements in chronic
bowel symptoms in patients randomized to the study
drug [19,20]. Other randomized studies using probiotics
during pelvic radiotherapy for diarrhea prophylaxis have
demonstrated a decrease in the mean number of bowel
movements and the incidence of diarrhea [21-23]. Similar
results have been obtained in our study; the group receiv-
ing lactobacillus acidophilus plus bifidobacterium
bifidum experienced less grade 2 or 3 diarrhea and
required less anti-diarrheal medication compared to the
placebo group. Stool consistency was also better in the
treatment group than the study group, but no difference
in white and red cell count was seen. One possibly signifi-
cant difference of our study to those with negative symp-
tomatic results is the use of a combination of bacterial
strains (lactobacillus acidophilus and bididobacterium
bifidum) rather than just a single strain. Delia et al. [22]
suggested that the use of several selected strains could
enhance the competitive interaction with the intestinal
flora. Thus the relative success of our study may be due to
the strains of bacteria used, the probiotic concentration
or the synergistic effect of combining more than one
strain. In this study, we did not perform the stool culture,
this could be the weakness of the study (it may be the
other cause of diarrhea), anyway, we perform the white
blood cell count in stool to help us to discriminate the
infectious diarrhea. We conclude that we can use live lac-
tobacillus acidophilus plus bifidobacterium bifidum for
diarrhea prophylaxis during pelvic radiation therapy with
concomitant cisplatin for locally advanced cervical can-
cer, with favorable reductions in symptoms.
Table 1: Baseline characteristics
Characteristics Placebo group
(n = 31)
Lactobacillus acidophilus plus 
bifidobacterium bifidum (Infloran®) 
group
(n = 32)
p-value
Median age (year) 52 47 0.146§
Stage of cervical cancer 0.80¶
IIB, n (%) 18 (58.1) 17 (53.1)
IIIB, n (%) 13 (41.9) 15 (46.9)
ECOG performance status 0.08¶
0, n (%) 29 (93.5) 24 (75.0)
1, n (%) 2 (6.5) 8 (25.0)
Whole pelvis Radiotherapy 
technique
0.60¶
AP-PA technique, n (%) 22 (71.0) 20 (62.5)
4-field box technique, n (%) 9 (29.0) 12 (37.5)
Tests: ¶ Fisher's exact test; § Mann-Whitney.Chitapanarux et al. Radiation Oncology 2010, 5:31
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Table 2: Treatment outcome
Characteristics Placebo group
n = 31
no. (%)
Study group
n = 32
no. (%)
p-value
Median overall treatment time 
(days)
51 48 0.05§
Median weight change from 
the beginning to the last 
treatment (kg)
-2.5 -2.4 0.66§
Diarrhea 0.002Θ
Grade I 17 (55) 29 (91)
Grade II, III 14 (45) 3 (9)
Anti diarrhea drug used 0.03¶
No 21(68) 29(91)
Yes 10(32) 3(9)
Stool <0.001Θ
Soft, Form 11(35) 26 (81)
Loose 20 (65) 6 (19)
White blood cell in stool 0.08¶
No 24 (77) 30 (94)
Yes 7 (23) 2 (6)
Red blood cell in stool 0.11¶
No 28 (90) 32(100)
Yes 3 (10) 0(0)
Tests: ¶ Fisher's exact test; § Mann-Whitney; Θ Chi-Square.Chitapanarux et al. Radiation Oncology 2010, 5:31
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